title: Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.
abstract: OBJECTIVE
  The aim of this study was to compare the performance of two high-throughput strategies for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) RNA nucleic acid technology (NAT) screening in a volunteer blood-donor population.
  
  
  METHODS
  The semiautomated Chiron Procleix HIV-1/HCV transcription mediated amplification (TMA) assay was used to screen 1 439 765 donations in two different testing configurations. Three sites (termed PDT sites) performed a mixture of individual donation (ID) and minipool (MP) testing, where 1 113 288 donations were screened as pools of 24 and an additional 32 003 donations were screened in ID format. A further two sites (termed SDT sites) screened 294 474 donations exclusively in ID format.
  
  
  RESULTS
  A significantly higher proportion of initial NAT reactives that failed to react on follow-up testing [termed non-repeatably reactive (NRR)] was observed for ID testing at SDT sites than at PDT sites (0.082 vs. 0.047%: P < 0.01). Within the PDT sites, however, there was no significant difference between the NRR rate for MP or ID samples (0.037 vs. 0.047%; not significant). There was a significant difference in failed run rates between PDT and SDT sites (P < 0.01), with PDT sites having a higher run failure rate owing to non-amplification of the internal control. The PDT sites also had a significantly higher overall invalid sample rate. However, the invalid sample rate, specifically caused by known equipment failure, was significantly higher in the SDT sites, possibly attributable to greater usage (P < 0.0001). Four HCV NAT-positive/antibody-negative samples were identified in the course of the study.
  
  
  CONCLUSIONS
  The comparison of the performance of PDT with SDT sites identified only minor differences that did not adversely impact on the timely release of blood products. Although both ID and MP strategies showed excellent specificity, irrespective of site configuration, the significantly increased NRR rate, observed exclusively for ID testing performed at SDT sites, indicates a potential for contamination that may limit the number of samples that can optimally be processed using ID testing. The performance data for ID testing in particular should serve as a useful benchmark for evaluating candidate NAT systems that are fully automated.
authors.affiliation: Australian Red Cross Blood Service, Brisbane, Australia Australian Red Cross Blood Service, Perth, Australia.
authors.forename: L
authors.initials: L
authors.lastname: Mison
authors.forename: C R
authors.initials: CR
authors.lastname: Seed
authors.forename: A R
authors.initials: AR
authors.lastname: Margaritis
authors.forename: C
authors.initials: C
authors.lastname: Hyland
mesh_terms: D001315:Australia / Q000453:epidemiology; D001782:Blood Donors; D003951:Diagnostic Errors; D015658:HIV Infections / Q000175:diagnosis*; D015497:HIV-1 / Q000235:genetics; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000175:diagnosis*; D006801:Humans; D008403:Mass Screening / Q000379:methods* / Q000592:standards; D021141:Nucleic Acid Amplification Techniques / Q000379:methods* / Q000592:standards; D012367:RNA, Viral / Q000097:blood; D012680:Sensitivity and Specificity; D013997:Time Factors
chemical_list: D012367:RNA, Viral